Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease
Keywords:
obesity, dyslipidemia, Vitamin E, saroglitazar, Asia-pacific
Abstract
Metabolic syndrome (MS) and Non-Alcoholic Fatty Liver Disease (NAFLD) spectrum disorder share common
risk factors namely obesity, hypertension, diabetes mellitus, and dyslipidemia, and hence, there is evidence
now to show that NAFLD may actually be a hepatic manifestation of MS. Moreover, the presence of NAFLD
in a patient with metabolic syndrome increases the risk of cardiovascular events and other co-morbidities.
Hence there is a need to develop an integrated preventive and therapeutic approach for both these conditions
and not treat them as separate entities.
References
1. Anjana RM, Pradeepa R, Deepa M, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/ or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research- INdiaDIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54:3022–3027
2. National Cholesterol Education Program (NCEP) Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143– 3421.
3. Almeda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas CA. Meta- bolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol. 2009;8:S18–S24
4. Duseja A, Das A, Das R, et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci. 2007;52:2368–2374.
5. Madan K, Batra Y, Gupta DS, et al. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol. 2005;24:251–255.
6. Jain, M., et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2017 Nov 21.
7. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
2. National Cholesterol Education Program (NCEP) Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143– 3421.
3. Almeda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas CA. Meta- bolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol. 2009;8:S18–S24
4. Duseja A, Das A, Das R, et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci. 2007;52:2368–2374.
5. Madan K, Batra Y, Gupta DS, et al. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol. 2005;24:251–255.
6. Jain, M., et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2017 Nov 21.
7. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
Published
2019-12-30
How to Cite
Dr. Kaushal Y. Vyas , Dr. Jigar K. Patel. (2019). Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. The Indian Practitioner, 72(12), 29-33. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/899
Section
Clinical Practice
